Public Company Limited’s subsidiary company (“The Company”), Joint Venture Ureka UU co., ltd. (“UU”), in which the company hold 90% of the share. The company plans to increase the shareholding to 99%. On
Company and its subsidiary for the fiscal year ended on 31 December 2019 as follows; Statements of Comprehensive Income Revenue from medical treatment The Company generated the revenue from medical
) (32.24) (2.25) (6.98) Share of profit of investment in associate 0.88 0.67 0.21 31.34 Tax expense (63.40) (59.04) (4.36) 7.38 Profit for the year 296.01 283.21 12.81 4.52 Owners of the Company 259.14
) Total comprehensive loss for the period (63.67) (61.60) (2.07) 3.36 Non-controlling interests (4.30) (3.39) (0.91) 26.68 Equity holders of the Company (59.26) (57.72) (1.54) 2.67 Basic loss per share
comprehensive loss for the period (63.67) (61.60) (2.07) 3.36 Non-controlling interests (4.30) (3.39) (0.91) 26.68 Equity holders of the Company (59.26) (57.72) (1.54) 2.67 Basic loss per share (0.08) (0.08
development of the waste disposal for approximately 15 days at Map Ta Phut facility and the change in the waste treatment procedures at Samaedam facility. These two factors directly affect the delay in some of
Microsoft Word - MDA_E ไตรมาสที่ 2-2560.doc Management Discussion and Analysis: MD&A 1. Company Situation Revenue from the waste treatment business for Q2/2017 has slightly improved due the acquiring
Microsoft Word - MD&A Q3-60_E .doc Management Discussion and Analysis: MD&A 1. Company Situation Revenue from the waste treatment business for Q3/2017 has slightly decreased due to the maintenances
. The revenue of waste treatment has slightly changed while the revenue of real estate business has decreased. The company profits from sales of land held for future development. The company and its
with fair treatment and transparency, and increase flexibility for management of member contribution. Most respondents agreed with the proposed amendments and suggested further details for the